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1. Introduction 
Primary membranous glomerulonephritis (MGN) is a major glomerular disease causing 
proteinuria in humans (Jones, 1957).  It is the prototype of an autoimmune disease (Couser, 
et al., 1978) characterized by sub-epithelial immune deposits within glomeruli. Its 
pathogenesis remains still unknown. Immune deposits are formed by IgG4, their respective 
antigen and complement. The definition of the immune deposit architecture has been a main 
focus of the pathology research for years but  advances were restricted, until recently, to 
animal models of the disease, in particular to Heymann nephritis (HN) (Heymann, et al., 
1959; Heymann, et al., 1952; Van Damme, et al., 1978). Unfortunately, results from 
experimental HN cannot be readily exported to human MGN since the major antigen of 
immune deposits in rat is not present in human glomeruli. Therefore different podocyte 
antigens are involved in human MGN and their identification is a fundamental step in 
understanding human pathology. Technology problems, mainly concerning dissection of 
glomeruli and purification/characterization of glomerular antibodies from human biopsies, 
have limited the experimental approach in humans for years. 
In the last 5 years, human MGN has become the topic of renewed nephrologic research. 
Debiec et al. (Debiec, et al., 2002, 2004) first showed that neutral endopeptidase (NEP) 
emerges as podocyte antigen in a rare form of congenital MGN due to maternal NEP 
deficiency and alloimmunization during pregnancy. More recently, the existence of three 
new glomerular auto-antigens, i.e. phospholipase A2 receptor (PLA2R), aldose reductase 
(AR) and superoxide dismutase 2 (SOD2) have been proposed by independent groups 
(Beck, et al., 2009; Prunotto, et al., 2010).  
Technology evolution in the field of laser capture and proteomics allowed a direct 
experimental approach in humans, a crucial step for a direct analysis ‘in vivo’. It is now clear 
that IgG4 eluted from glomeruli of MGN patients recognize a panel of podocyte proteins 
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that have been only in part characterized and that represent good candidates for being 
involved in the pathogenesis of MGN as “auto-antigens”. 
The same approach might be extended to different renal auto-immune pathologies. 
However, before proceeding, the scientific community needs a consensus on criteria and 
technologies that should be utilized for recognizing and validating auto-antigens.  
2. Animal models 
Heymann nephritis (Heymann, et al., 1952, 1959) is the animal model most frequently used 
for studying mechanisms implicated in the process of deposition of antibodies within 
glomeruli. Passive Heymann nephritis is induced in susceptible rat strains by injection of 
heterologous antisera from sheep or rabbit immunized with a crude extract of rat proximal 
tubular antigens known as Fx1A. This model is highly similar to human MGN: renal 
pathology in HN is constantly charachterized by the presence of glomerular sub-epithelial 
immune deposits. Heymann nephritis is quite simple to be produced and has offered for 
years the unique chance to study the structure of immune deposits and the mechanisms 
involved in their formation. This goal has been completed many years ago. Several studies, 
between 1980 and 1990, demonstrated that megalin is the target antigen of sub-epithelial 
IgG. Complement factors, mainly  C5b-9, and other ancillary proteins such as  receptor 
associated protein (RAP) and anti-RAP IgG complete the structure of immune deposits 
(Couser, et al., 1978; Kerjaschki, 2004; Kerjaschki & Farquhar, 1982; Kerjaschki, et al., 1987, 
1992; Saito, et al., 1994; Salant, et al., 1980a, 1980b; Van Damme, et al., 1978).  
The presence of IgG directed against a podocyte antigen triggers the complement cascade 
that ends with the formation of C5b-9, the key mediator of podocyte damage in MGN. C5b-9 
aggregation on the podocyte membrane causes the activation of the epithelial cell.  The 
podocyte starts the production of a cascade of mediators with phosphorylation of PKC and 
formation of free oxygen radicals (Cybulsky, et al., 2000). The result is a rearrangement of 
the cytoskeleton and the consequent loss of cell junction that leads to a pathologic alteration 
of the glomerular filter and to the appearance of proteinuria.  
Immune deposits also contain clusterin (Ghiggeri, et al., 2002; Rastaldi, et al., 2006), a natural 
binder of megalin, that probably represents an endogenous inhibitor of C5b-9.  
The definition of pathology features and physiopathology events in Heymann nephritis 
represented a breakthrough in research of renal autoimmunity. Unfortunately, in spite some 
of the components above have been detected in human MGN (i.e. C5b-9, clusterin), 
Heymann nephritis could not be utilized as a direct model of human MGN because megalin 
is not present in human glomeruli. Moreover, many years later, it was described that 
megalin structural homolog, the LDL-receptor, is not recognized by circulating IgG4 in 
human MGN (Bruschi, et al., 2009).  
Diverse animal models of membranous nephropathy have been developed and different 
podocyte antigens have been identified such as neutral endopeptidase in rabbit,  and 
dipeptidyl peptidase IV in mouse (Table 1) (Assmann, et al., 1992; Ronco, et al., 1989). These 
proteins are present in human glomeruli; however they were not identified in immune 
deposits and their involvement in idiopathic MGN was never proved (Allegri, 1997).  
After all, animal models showed the heterogeneity of potential podocyte antigens in MGN 
and straightened the concept of ‘in situ’ formation of immune deposit. Problems related to 
the translation of the lesson from animal models to human beings slowed progression in 
understanding of mechanisms of human MGN. After twenty years, however, new insights 
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were generated by the observation of familial models of MGN and from the characterization 
of antigens involved in their pathogenesis.  
 
 Animal Models  Ref.  
    
Megalin  rat 
Kerjaschki & 
Farquhar, 1982 
Dipeptidyl peptidase IV  rat, mouse, rabbit 
Assmann, et al., 
1992 
Neutral endopeptidase  rabbit 
Ronco, et al., 
1989 
    
 Neonatal MGN   
    
Neutral endopeptidase  humans 
Debiec, et al., 
2002 
    
 Idiopathic MGN   
    
Phospholipase A2 receptor  humans Beck, et al., 2009 
Aldose reductase  humans 
Prunotto, et al., 
2010 
Mn-superoxide dismutase  humans 
Prunotto, et al., 
2010 
Alpha enolase  humans 
Bruschi, et al., 
2011 
Others  humans 
Bruschi, et al., 
2011 
Table 1. Glomerular antigens in experimental models and in human MGN 
3. Human MGN 
3.1 Neonatal MGN 
Seminal studies by Debiec and Ronco (Debiec, et al., 2002; Debiec, et al., 2004) represented  
a fundamental passage on the road of comprehension of human MGN many years after  
the definition of HN. These authors’ contributions led to the definition of neutral 
endopeptidase as the auto-antigen in rare forms of familial congenital MGN (Table 1). 
Antibodies against neutral endopeptidase was first recognized in a newborn presenting 
with congenital nephrotic syndrome. Renal histology demonstrated MGN. The basis of the 
pathogenesis was the mother, carrying a genetic deficiency of neutral endopeptidase 
because of an homozygous deletion in MME, the corresponding gene. She became 
alloimmunized against neutral endopeptidase during a prior pregnancy, ended with 
miscarriage. Anti- neutral endopeptidase antibodies were then transferred to the fetus 
during the successive pregnancy and congenital MGN developed in the newborn while 
disappearing thereafter.  
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This elegant model could therefore demonstrate, for the first time, the pathogenic role of a 
podocyte antigen in human MGN. Similar mutations of MME were found in three further 
families that had in common at least one case of congenital MGN. Even if the presence and 
the involvement of antibodies against neutral endopeptidase was clearly demonstrated, the 
prevalence of this form of MGN is probably very low and these results cannot be translated 
directly in idiopathic MGN.  
There is, in fact, now much debate about considering neutral endopeptidase an auto-
antigen in non-familial MGN. In fact, circulating anti- neutral endopeptidase IgG4 can be 
detected in a minor part of patients with primary MGN but this antigen is not recognized 
by IgG4 eluted from micro-dissected glomeruli (Ghiggeri, personal observation). Further 
studies are required to rule out the involvement of neutral endopeptidase in idiopathic 
MGN. 
3.2 Technology advances for ‘in vivo’ studies 
New technologies in the fields of tissue micro-dissection and protein characterization have 
recently played an essential role in discovering new auto-antigen in human MGN. They 
allowed for the first time the analysis of minute amounts of human tissue from a diagnostic 
renal biopsy. In fact, micro-dissection and proteomics are of fresh development but have 
been rapidly adapted to renal tissue studies (Murtas, et al., 2011).  
The basic approach starts with  the laser dissection of glomeruli from cryo-sections of renal 
tissue. This technique is highly specific and reproducible. It permits to obtain  purified 
glomeruli from which antibodies can be eluted utilizing osmotic gradients and further 
characterizated.  
Western blot analysis coupled with mass spectrometry is the second basic technique for 
characterizing auto-antibodies. In this case, podocyte proteins are first separated with 
mono-dimensional electrophoresis in both denaturing and non-denaturing conditions (a few 
proteins are not recognized after mild denaturing treatment) or with two-dimensional gel 
electrophoresis and they are then incubated with glomerular eluates. The binding of specific 
IgG4 with podocyte antigens is detected with anti-IgG4 antibodies and revealed with 
chemiluminescence. Finally, podocyte proteins recognized by IgG4 are characterized by 
mass spectrometry. 
Western-blot/mass spectrometry are also utilized for the characterization of circulating 
antibodies: serum replaces eluted antibodies.  
3.3 Glomerular antigens in human MGN 
In terms of general discussion it is rational to propose at least three basic characteristics that 
should be fulfilled by a protein when considered as an auto-antigen in idiopathic MGN.  
The first one is that the candidate auto-antigen is expressed by podocytes at least in 
pathological conditions and that it is recognized by IgG4 eluted from micro-dissected 
glomeruli. The second criterion is that the candidate antigen co-localizes with IgG4 (and 
possibly with C5b-9) in glomerular sub-epithelial immune deposits.  The final condition is 
that IgG4 against the protein must be detected in MGN patients sera at least during the overt 
phase of the disease.  
A question apart is specificity, that is a major issue of the consensus debate.  
Therefore, characterizing an auto-antigen requires a multistep approach: first of all 
immunoglobulins are eluted from MGN glomeruli. Then their target is evaluated by 
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western-blot against podocyte proteins. The evaluation of co-localization within the immune 
deposits, isotype analysis and titration of circulating antibodies are further steps of the same 
project. Following this scheme three podocyte proteins have been characterized as putative 
auto-antigens: phospholipase A2 receptor (PLA2r), Mn-superoxide dismutase (SOD2), 
aldose reductase (AR).   Alpha enolase is a recent finding (Table 1 and Figure 1). Few others 
are still in progress. 
PLA2r is a member of the mannose-receptor family that is normally expressed on the 
podocyte membrane in humans (East & Isacke, 2002; Lambeau & Lazdunski, 1999). It binds 
circulating phospholipase A2 but its physiological role is still uncertain. In MGN auto-
antibodies recognize PLA2r only in its native configuration that is dependent on disulphide 
bonds and this is the reason why this protein requires stringent conditions of analysis 
rigorously in non-denaturing environment. It is reasonable that conformation of PLA2r 
plays a key role in auto-antibodies formation and binding. Studies (Beck, et al., 2009; 
Hofstra, et al., 2011) in limited groups of patients with idiopathic MGN revealed high 
circulating levels in a significant portion of patients and their absence in cases of secondary 
MGN suggesting a direct implication as causative factor.  
SOD2 is a key anti-oxidant mitochondrial enzyme implicated in transformation of 
superoxide ions into hydrogen peroxide and diatomic oxygen (Son, et al.,2008). In the 
kidney, SOD2 is widely expressed in tubular epithelial cells, especially in the cortex, where 
it plays a central role in preserving the kidney during ischemia/reperfusion events but it has 
never been reported in normal glomeruli. In fact, SOD2 is neo-expressed in podocytes and 
in sub-epithelial immune deposits of patients with MGN. (Figure 1) (Prunotto, et al., 2010). 
This suggests that conditions associated with hyperexpression and membrane displacement 
may be implicated in the auto-immune process.  
AR belongs to the family of aldo-keto reductases involved in catalysis of NADPH-
dependent reduction of aliphatic and aromatic aldehydes and ketones. It is usually a 
cytoplasmic enzyme. It converts glucose into sorbitol and it is involved in regulation of 
tissue tonicity and osmolarity (Williamson, et al.,1993). As for SOD2, localization of AR 
within the normal kidney is limited to tubular epithelial cells of the medulla and it is 
absent in glomeruli. In MGN patients it become detectable in glomeruli and it co-localizes 
with deposed IgG4  (Figure 1) (Barski, et al., 2005; Terubayashi, et al., 1989; Prunotto, et al. 
2010). 
The fourth antigen, alpha enolase (Bruschi, et al., 2011) is one of the most abundant proteins 
in cytosol where it participates in the glycolysis process as catalyst of the dehydration of 2-
phosphoglycerate to phosphoenolpiruvate; it is particularly expressed in tubular kidney 
cells and in liver epithelia. A plasma membrane localization has also been described. Several 
autoimmune diseases are associated with circulating anti-alpha enolase antibodies; however 
a pathogenetic role has never been demonstrated in any pathological entity   (Wistow, et al., 
1988; Miles, et al., 1991; Aaronson, et al., 1995; Sabbatini, et al., 1997; Gitlits, et al., 2001). The 
presence of this kind of auto-antibodies in sera of MGN patients is not a new finding 
(Wakui, et al., 1999). However, alpha enolase neo-expression in MGN glomeruli and its co-
localization with IgG4 straighten the concept that it is another auto antigen implicated in 
MGN pathogenesis (Figure 1).  
Glomerular immunoglobulin eluates interact with other podocyte membrane proteins 
(Figure 2). They need to be identified and they have to be tested with the approach 
described above. Probably, the list of MGN antigens will further increase in a few years.   
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Fig. 1. Glomerular expression of aldose reductase, Mn-superoxide dismutase and alpha 
enolase in MGN patients. Immunofluorescence on renal cryo-sections analyzed with 
confocal microscopy. Merged images show co-localization between antigens and IgG4. 
3.4 Antibody isotypes and clinical correlations 
IgG4 typically represents the main body of  immune deposits in both Heymann nephritis 
and human MGN. IgG1 and IgG2 are also present.  
In sera IgG4 against the described glomerular antigens are prevalent. However,  also IgG1 
can be detected in case of auto-antibodies against alpha enolase. Circulating auto-antibodies 
are made up of  the same he same IgG4/IgG1  isotypes indicating a good homology between 
the circulating and the renal counterparts (Figure 2). How the IgG isotype can influence 
pathogenesis of MGN is still matter of debate since a few issues are not clear.  The first one 
is related to the described inability of IgG4 to activate complement, that might suggests an 
independence between IgG4 deposition and C5b-9 formation. Another concern is about 
IgG1: their role in MGN need to be re-evaluated.  
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Fig. 2. (a) Circulating immunoglobulin isotypes referred to autoantibodies againsts AR, 
SOD2 and alpha enolase. In the former two cases the predominant isotype is IgG4, in the 
case of alpha enolase both IgG1 and IgG4 are detectable. (b) Western-blot with IgG4  eluted 
from glomeruli of patients with MGN. A few podocyte proteins are recognized . Three of 
them have been characterized as aldose reductase (AR), Mn-superoxide dismutase  (SOD2) 
and alpha enolase.  
The determination of circulating levels of antibodies against  auto-antigens and their clinical 
correlation is now in progress.  Only small cohorts of patients have been evaluated. 
Moreover, in each population only one antigen have been tested (Beck, et al., 2009; Prunotto, 
et al., 2010; Debiec & Ronco, 2011; Hofstra, et al. 2011). A correlation of autoantibodies level 
with proteinuria has been proposed, suggesting that high circulating titers are in 
relationship with phases of immunological activity of the disease. A strong association with 
clinical outcome is still lacking. It is also an important issue to establish a correlation among 
antibodies against different antigens; such stuidies are on the way. Probably they will help 
in establishing a hierarchy between antigens, if it exists.  
Another key aspect would be to find out a correlation between glomerular deposits and 
serum levels or clinical outome. Surrogate biomarkers are needed for guiding treatment and 
long-term follow-up in MGN patients. 
3.5 Predisposing factors 
Many immunological or infectious diseases, neoplasms and toxic or farmacological agents 
have been associated with MGN. In these situations MGN is considered “secondary” to the 
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respective pathological entity, even if the presumptive antigen has never been isolated from 
the affected glomeruli. A classical pathogenetic theory affirms that the causative agent can 
initiate the pathological process in genetically susceptible individuals.  
In primary MGN some association has been proved with HLA alleles: in particular HLA-B8, 
HLA-B18 and HLA-DR3. The latter has been described probably confering a threefold 
increased risk of the disease (Dyer, et al., 1992; Klouda, et al., 1979)  
More recently a genomewide association study conducted in three white European 
population reported an evident association of MGN with single nucleotide  polymorphism 
(SNP) in PLA2R gene and, more strongly, in HLA-DQ alpha chain 1 (HLA-DQA1). The 
authors do not report any association in AR and SOD2 genes. The MGN risk in relation with 
SNPs in PLA2R gene is proposed also in two other Asian studies (Stanescu, et al., 2011).  
Even these data are not conclusive, they might suggest a “two hits” model also for the 
pathogenesis of MN. In fact, a variation in some component of  the immune system (HLA-
DQ variation) might confer an autoimmunity predisposition. Successively, an alteration, 
congenital or acquired, of the localization or of the structure of an antigen (PLA2R or 
others), can make the antigen itself became the target of the disregulated immune system.  
4. Conclusions 
Research on MGN pathogenesis restarted recently, after many years of  frustrating findings. 
Technology evolution was the major incentive to new stuidies.   
The finding of at least four auto-antigens implicated in the pathogenesis of MGN, needs an 
explanation in a complex pathogenetic theory. Nowadays, it seems reasonable that 
mechanisms related to the formation of auto-antibodies against membrane proteins, such as 
PLA2r, are different from auto-antibodies against antigens typically localized inside the cell, 
such as SOD2 (mitochondrial), and AR or alpha enolase (cytosolic). Antibody promiscuity 
can be in some way justified by mimicry in case of membrane proteins whereas, for 
molecules such as SOD2, AR or alpha enolase, mechanisms of de-localization should play a 
role. 
Anyway, before a complete elucidation of MGN pathogenesis several studies have to be 
performed: more clinical data, new insights on cellular localization of antigens and , maybe, 
new animal models are needed.  
There is a some kind of hierarchy between different targets of autoimmunity? The 
production of a first autoantibody stimulates podocyte expression of other auto-antigens 
and a new wave of immunization? There are types of autoantibody not correlated with 
clinical evolution that are only some kind of “epiphenomenon”? There are different clusters 
of MGN patients with different autoantibody profile? 
Many questions raise when considering recent discoveries on MGN. They will be correctly 
answered only if scientific community proceeds with shared approach in discovering and 
testing candidate antigens. Exciting times are coming for the researches involved in studies 
on MGN and other renal auto-immune diseases.  
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